Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
AssigneeCedars-Sinal Medical Center
InventorsDavid Q. Shih, Stephan R. Targan, Janine Bilsborough
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions related to Inflammatory Bowel Disease. Specifically TL1A drives regional intestinal inflammation and fibrosis and is differentially modulated by IFN gamma and IL-17a. In one embodiment, the present invention is a method of diagnosing a condition in a subject by determining the presence or absence of IFN gamma and/or IL-17 and diagnosing the subject.
Claims34
A method of treating an inflammatory bowel disease (IBD) related condition in a subject, comprising:
- providing a composition comprising an inhibitor of IL17 signaling;
- and
- administering a therapeutically effective dosage of the composition to the subject.
(canceled)
(canceled)
A method of treating inflammatory bowel disease (IBD) and/or fibrosis in a subject, comprising:
- diagnosing the IBD and/or fibrosis in the subject by determining the level of IFN gamma, IL-17 and/or TL1A expression;
- and
- treating the subject.
(canceled)
(canceled)
A method of treating an inflammatory condition in a subject, comprising:
- diagnosing the inflammatory condition based on the presence or absence of TL1A expression and one or more cytokines;
- and
- treating the subject.
A method of diagnosing an inflammatory bowel disease (IBD) and/or fibrosis subtype in a subject, comprising:
- obtaining a sample from the subject;
- subjecting the sample to an assay adapted to determining the level of IFN gamma, IL-17 and/or TL1A expression;
- and
- diagnosing the subtype,
- wherein an elevated level of IFN gamma and the presence of TL1A expression is indicative of a severe colitis, and
- wherein the reduced level of IL-17 is indicative of a less severe form of colitis, inflammation and/or fibrosis.
(canceled)
A method of prognosing inflammatory bowel disease (IBD) and/or fibrosis in a subject, comprising:
- obtaining a sample from the subject;
- subjecting the sample to an assay adapted to determining the level of IFN gamma, IL-17 and/or TL1A expression;
- and
- prognosing the IBD and/or fibrosis in the subject,
- wherein elevated level of IFN gamma and//or TL1A expression is indicative of a severe colitis, and
- wherein the reduced level of IL-17 is indicative of a less severe form of colitis, inflammation and/or fibrosis.
(canceled)
Dependencies are inferred from the claim text.